HUTCHMED (China) Limited
HCM
Positions held
Your positionsHCM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- HUTCHMED operates in the growing specialty and generic drug manufacturing sector, which is expected to expand as global healthcare demands increase.
- The company has a market cap of approximately $2.54 billion and a strong buy recommendation with a score of 44.00.
- In 2023, HUTCHMED reported a revenue of $837.999 million, with a gross margin of 54.12%.
- The company's earnings growth has been declining, with a significant drop of 96.5% reported.
- HUTCHMED's operating margin was only 2.57% in 2023, indicating challenges in profitability.
- The debt-to-equity ratio stands at 7.413, suggesting high leverage and potential financial risk.
Fundamentals
| Market cap | $2.38B | Enterprise value | $1.11B | Trailing P/E | 136.70 | Forward P/E | 52.74 |
| PEG | — | Price / book | 1.88 | Beta | 0.36 | Dividend yield | 0.00% |
| Revenue growth | 0.2% | Earnings growth | -96.5% | Gross margin | 13.3% | Operating margin | 0.3% |
| Profit margin | 3.3% | ROE | 1.5% | ROA | -1.2% | Debt / equity | 0.07 |
| Current ratio | 5.64 | Free cash flow | -$18.88M | Analyst recommendation | strong_buy | Mean target | $22.01 |
| 52w high | $16.33 | 52w low | $9.77 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $549M | $630M | $838M | $426M | — |
| Op margin | -6.5% | -6.4% | 2.6% | -95.3% | — |
| Net income | $457M | $37.7M | $101M | -$361M | — |
| Gross margin | 38.7% | 44.6% | 54.1% | 27.0% | — |
| Gross profit | $212M | $281M | $454M | $115M | — |
| Operating income | -$35.7M | -$40.6M | $21.5M | -$406M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · NIOX Group And 2 Other British Healthcare Stocks
2026-09-29 · HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
2026-09-28 · HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
2026-09-24 · GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
2026-09-24 · HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
2026-09-03 · HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
2026-09-03 · Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
2026-09-03 · HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
2026-09-03 · HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
2026-08-17 · HUTCHMED shares rise as lung cancer drug trial hits key targets
Price (daily)
Full chart · RSI · MACD · patterns